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ABSTRACT
Objective. Population-based surveillance data from California and Georgia for 
years 2004 through 2008 were linked to state death record files to determine 
the all-cause death rate among 12,143 patients identified with sickle cell 
disease (SCD). 
Methods. All-cause death rates, by age, among these SCD patients were 
compared with all-cause death rates among both African Americans and the 
total population in the two states. All-cause death rates were also compared 
with death rates for SCD derived from publicly available death records: the 
compressed mortality files and multiple cause of death files.
Results. Of 12,143 patients identified with SCD, 615 patients died. The 
all-cause mortality rate for the SCD population was lower than the all-cause 
mortality rate among African Americans and similar to the total population 
all-cause mortality rates from birth through age 4 years, but the rate was higher 
among those with SCD than both the African American and total population 
rates from ages 5 through 74 years. The count of deceased patients identified 
by using population-based surveillance data (n5615) was more than twice as 
high as the count identified in compressed mortality files using SCD as the 
underlying cause of death alone (n5297).
Conclusion. Accurate assessment of all-cause mortality and age at death 
requires long-term surveillance via population-based registries of patients with 
accurately diagnosed SCD. 
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Ongoing public health surveillance of sickle cell 
disease (SCD) is critical to understanding its course 
and outcomes. Such surveillance is vital for medical 
management, clinical and translational research, new 
therapy development, public health planning, and 
patient, family, and provider education. 
Multiple research studies have used data col-
lected through limited surveillance activities to better 
understand age at death for patients with SCD. Stud-
ies published in the 1970s showed a poor prognosis 
for patients with SCD, with a median age at death of 
approximately 14 years, high mortality in the first five 
years of life, and only about 15% of deaths occurring 
after age 30 years.1 Results from a 1978 study based 
on a newborn screening cohort in Jamaica found that 
13% of children with hemoglobin SS disease and 5% 
of children with hemoglobin SC disease died in the 
first two years of life.2 Follow-up studies in Jamaica 
confirmed this observation and showed that only 25% 
of deaths among those with SCD occurred in patients 
older than 30 years of age.3 
The Cooperative Study of Sickle Cell Disease, which 
followed SCD patients in the United States from 1978 
through 1988, reported patient survival in its academic 
center cohort, with a median age at death of 48 years 
for women and 42 years for men with hemoglobin SS 
disease, and 68 years for women and 60 years for men 
with hemoglobin SC disease.4 This study also reported 
that 50% of hemoglobin SS disease deaths occurred 
in patients older than 45 years of age. A 2001 study, 
using excess mortality simulation of a Jamaican cohort, 
predicted that 50% of SCD deaths would occur in those 
older than 53 years of age.5 Additional studies based on 
newborn screening cohorts enrolled in comprehensive 
care systems in the United States (published in 2004 
and 2010), the United Kingdom (published in 2007), 
and Brazil (published in 2014) indicated that mortal-
ity in the first five years of life was significantly lower 
than in the 1978 Jamaican report, with the expectation 
that 86% to 98% of children with SCD would live to 
adulthood.2,6–9 
However, not all recent research indicates similar 
findings in SCD mortality. A study using data from 
the National Center for Health Statistics’ (NCHS’s) 
compressed mortality (CM) files, 1999 through 2006, 
estimated the mean age at death for patients with SCD 
to be 39 years in 2006.10 In that study, among the 483 
SCD deaths in the United States reported during that 
year, 9% occurred in those aged 20 years or younger 
and 35% occurred in those older than 45 years of 
age. A study using NCHS’s multiple cause of death 
(MCOD) files, 1979 through 2005, to estimate age at 
death and death rates similarly found median ages at 
death among women and men with SCD to be 42 and 
38 years, respectively.11
One important caveat to previous mortality studies 
is that researchers relied on death certificate report-
ing of SCD10,11 or on populations seen at high-volume 
hematology clinics.2–9 Studies based on death certifi-
cates assumed accurate and complete coding in the 
death record, while the clinic-based studies may have 
been biased to include the sickest SCD patients, who 
are more likely to be seen at specialty care centers. 
To address these limitations, we used data on SCD 
patients from California and Georgia who were identi-
fied during the Registry and Surveillance System for 
Hemoglobinopathies project and linked them to all 
state death record files to estimate the all-cause mortal-
ity rate and mean and median ages at death for SCD 
in these two states.12 
METHODS
The National Institutes of Health-funded and Centers 
for Disease Control and Prevention (CDC)-directed 
Registry and Surveillance System for Hemoglobin-
opathies project collected and linked population-
based surveillance data from a variety of sources in 
California and Georgia for 2004 through 2008.12 These 
data sources included state administrative data and 
newborn screening records, as well as case reports of 
patients from hemoglobinopathy specialty treatment 
centers. All administrative data sources used Interna-
tional Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) codes, except for state death 
record files, which used International Classification of 
Diseases, 10th Revision (ICD-10) codes.13,14 
Data collection: California
In California, data were requested from state newborn 
screening (all SCD patients born 2000 through 2008); 
vital records (state-based MCOD files, all deaths in 2004 
through 2008); Office of Statewide Health Planning 
and Development: inpatient files (all records 2004 
through 2008) and emergency department files (all 
records 2005 through 2008); Medi-Cal/Medicaid (all 
individuals insured in 2004 through 2008 who had an 
SCD ICD-9-CM code [282.41, 282.42, 282.6, 282.60, 
282.61, 282.62, 282.63, 282.64, 282.68, 282.69]); hemo-
globinopathy specialty treatment centers: Children’s 
Hospital Los Angeles (all children and adults seen in 
2004 through 2008 who had an SCD diagnosis) and 
University of California San Francisco Benioff Chil-
dren’s Hospital Oakland (all children and adults seen 
in 2004 through 2008 who had an SCD diagnosis).
After cleaning, data for patients found in multiple 
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datasets were linked by deterministic matching using 
social security number and date of birth where suf-
ficient data were available, or by probabilistic algo-
rithm15 using weighted combinations of date of birth, 
sex, geographic area, facility attended, and diagnosis 
where sufficient data were unavailable. Details on data 
used, linkage, and results are available elsewhere.12,16
Data collection: Georgia
In Georgia, data were requested from state newborn 
screening (all SCD patients born 2004 through 2008); 
vital records (state-based MCOD files, all deaths in 2004 
through 2008); Georgia Hospital Association: inpatient 
files (all records in 2004 through 2008) and emergency 
department files (all records in 2004 through 2008); 
Medicaid (all individuals insured in 2004 through 
2008 who had an SCD ICD-9-CM code); Georgia’s 
Children’s Health Insurance Program (all individuals 
insured in 2004 through 2008 who had an SCD ICD-
9-CM code); Georgia’s State Health Benefit Plan (all 
individuals insured in 2004 through 2008 who had an 
SCD ICD-9-CM code); and hemoglobinopathy specialty 
treatment centers: Georgia Comprehensive Sickle Cell 
Center at Grady Memorial Hospital (all children and 
adults seen in 2004 through 2008 who had an SCD 
diagnosis), Georgia Health Sciences University (all 
children and adults seen in 2004 through 2008 who 
had an SCD diagnosis), and all three campuses of 
Children’s Healthcare of Atlanta (all children seen in 
2004 through 2008 who had an SCD diagnosis). 
Few data sources included social security numbers 
or Medicaid identification numbers consistently; 
therefore, deterministic matching of patients was not 
feasible for most datasets in Georgia. Each dataset was 
de-duplicated and datasets were then matched, one at 
a time, using a probabilistic algorithm that assigned 
differing weights to identifying variables, such as date 
of birth, patient’s name, mother’s name (for children), 
sex, county, telephone number, and address. Details on 
data used, linkage, and results are available elsewhere.12
Inclusion criteria
This study included patients (referred to as SCD 
patients) who were reported by newborn screening 
and/or one of the reporting hemoglobinopathy spe-
cialty treatment centers with a laboratory-confirmed 
diagnosis (n=6,263). Patients with a combination 
of two or more health-care encounters with SCD 
ICD-9-CM codes and one or more expected SCD 
treatments, procedures, or complications (n=5,880) 
were also included.12,16 This study did not include indi-
viduals having one or more health-care encounters 
with an SCD ICD-9-CM code but no evidence of an 
expected SCD treatment, procedure, or complication 
(n517,642). 
Mortality analyses
All SCD patients were linked to state-based MCOD 
files for 2004 through 2008 by using social security 
numbers or full names and dates of birth. All-cause 
mortality rates for the SCD population were calculated 
as the number of SCD patients who died from 2004 
through 2008 in a given age group divided by the 
total number of SCD patients in that age group dur-
ing the same period. The result was then divided by 
five for an annual average. For some SCD patients, the 
linked death records did not include SCD as a cause 
of death but otherwise met the inclusion criteria and 
were included in these analyses. Conversely, deaths 
in the state-based MCOD files that included SCD as a 
cause of death, but did not fit our inclusion criteria, 
are described separately and were not included in 
calculations of mortality rates or age at death. 
All-cause mortality rates for the African American 
population and the general population in Georgia 
and California for 2008 only were derived by using 
CDC’s Wide-ranging Online Data for Epidemiologic 
Research (WONDER) MCOD queries.17 Data on 
SCD-coded deaths were also queried from the NCHS 
MCOD database and the NCHS CM database (also via 
CDC WONDER) for California and Georgia for years 
2004 through 2008, for comparison with published 
SCD mortality surveillance reports and methods.10,11,17,18 
NCHS MCOD files are related to the state-based 
MCOD death files; both sets of files are derived from 
death certificates, both allow for coding of up to 24 
underlying and contributing causes of death, and the 
methodology for coding is consistent across all states. 
State-based MCOD files, however, have patient-level 
data, include some identifiers, and are only offered 
to researchers and public health agencies for analysis 
under specific circumstances. NCHS MCOD files are 
reported to the public as aggregated data. In contrast 
with NCHS and state-based MCOD files, NCHS CM 
data indicate only the reported underlying cause of 
death and not contributing causes. As with the NCHS 
MCOD files, NCHS CM data are reported publicly as 
aggregate counts and rates and are not reviewable 
as individual patients. Also of note, both the NCHS 
MCOD and CM reports suppress results when a cell 
size is ,10; therefore, information for some age groups 
may be incomplete if fewer than 10 patients in that 
age group died during the period of interest. We used 
ICD-10 coding to identify patients with SCD from the 
NCHS CM and NCHS MCOD files included in this 
study (D57.0, D57.1, D57.2, D57.8).
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We calculated all-cause mortality rates for the SCD 
population in the two states (deaths per 1,000 patients) 
by age group at time of death, all-cause mortality rates 
for the African American population (deaths per 
1,000 population), and all-cause mortality rates for all 
populations (deaths per 1,000 population) from both 
states. We calculated mean, standard deviation (SD), 
and median age at death by sex and overall. The data 
analysis for by this study was generated using SAS® 
version 9.3.19 
RESULTS
Of the 12,143 SCD patients identified through pop-
ulation-based surveillance in California and Georgia 
in 2004 through 2008 and who met the inclusion 
criteria for this study, 615 were linked to records in 
state-based MCOD files. Among these 615 records, 
143 were patients with known genotype and 472 were 
patients with unknown genotype. Proportions among 
age groups and sex were similar across the two states. 
Among these 615 SCD deaths, 16% of deaths occurred 
before 25 years of age and 45% of deaths occurred 
after 44 years of age (Table). 
All-cause mortality rates for the SCD population (1.5 
deaths per 1,000 patients) were lower than the all-cause 
mortality rates for African Americans (2.8 deaths per 
1,000 population) in the youngest age group but rose 
steadily compared with the all-cause African American 
rates thereafter, until the oldest age group (Figure 1). 
For SCD patients, the mean (SD) age of death was 43.4 
years (16.8) for females (median: 43.5 years) and 40.8 
years (17.0) for males (median: 41.9 years); the mean 
age of death for all patients was 42.2 years (16.9) and 
median age of death was 42.8 years. 
Data from the NCHS CM files showed 297 patients 
in Georgia and California with an underlying cause 
of death of SCD in 2004 through 2008; data from the 
NCHS MCOD files showed 513 patients with an under-
lying or contributing cause of death of SCD in 2004 
through 2008; and data from population-based surveil-
lance showed 615 SCD deaths in 2004 through 2008 
(Figure 2). Sub-analysis of the NCHS data by age group 
produced information on 258 deaths from the CM file 
and 482 deaths from the MCOD file; these smaller 
numbers resulted from the suppression of cells with 
fewer than 10 deaths. The proportion of SCD deaths 
in the older age groups identified through population-
based surveillance ($45 years of age: 276/615, 45%) 
was larger than that identified by NCHS data (CM files: 
95/297, 32%; MCOD files: 205/513, 40%). Deaths 
among the oldest age groups ($65 years) occurred 
in 53/615 (9%) of SCD patients identified through 
population-based surveillance, 0/297 (0%) in the same 
Table. Number of deaths for sickle cell disease patients identified using 2004–2008 population-based surveillance 
data, California and Georgia 
California and Georgia 
combined California Georgia
Characteristic
Number of 
SCD patients
Number of 
SCD deaths 
(percent)a
Number of 
SCD patients
Number of 
SCD deaths 
(percent)a
Number of 
SCD patients
Number of 
SCD deaths 
(percent)a
Combined 
mortality  
rate per  
1,000 patients 
per year
Total 12,143 615 5,135 327 7,008 288 10.1
Age group (in years)
 0–4 1,738 13 (2) 746 8 (2) 992 5 (2) 1.5
 5–14 2,686 18 (3) 1,096 10 (3) 1,590 8 (3) 1.3
 15–24 2,435 68 (11) 979 36 (11) 1,456 32 (11) 5.6
 25–34 1,986 101 (16) 781 46 (14) 1,205 55 (19) 10.2
 35–44 1,496 139 (23) 656 72 (22) 840 67 (23) 18.6
 45–54 1,097 142 (23) 524 79 (24) 573 63 (22) 25.9
 55–64 474 81 (13) 236 45 (14) 238 36 (13) 34.2
 65–74 164 32 (5) 83 19 (6) 81 13 (4) 39.0
 $75 67 21 (3) 34 12 (4) 33 9 (3) 62.7
Sexb
 Male 5,512 289 (47) 2,337 152 (46) 3,175 137 (48) 10.5
 Female 6,630 325 (53) 2,798 175 (54) 3,832 150 (52) 9.8
aColumn percentages may not total to 100 because of rounding.
bOne Georgia patient was missing information on sex.
SCD 5 sickle cell disease
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age group in the NCHS CM files, and 13/513 (3%) in 
the NCHS MCOD data.
Among the 615 SCD patients linked to state-
based MCOD data, 352 (57%) had an underlying or 
 contributing cause of death coded as SCD, and the 
remaining 263 (43%) did not have SCD listed as a cause 
of death (Figure 3). In addition to the 615 state-based 
MCOD death certificates linked to SCD patients, 155 
deaths were found in the state-based MCOD data (84 
in California, 71 in Georgia) with an SCD ICD-10 code 
(excluding the code for sickle cell trait, D57.3), but 
no other evidence of SCD in the linked data sources. 
Among these 155 deaths were 81 deaths with an SCD 
code as the underlying cause of death and 74 with an 
SCD code as a contributing (but not underlying) cause 
of death. This group had a mean (SD) age of death 
of 45.0 years (17.8) and median age of death of 46.4 
years; however, these 155 patients were not included in 
the analyses because they did not meet the inclusion 
criteria for our study.
DISCUSSION
This study was the first population-based SCD mortality 
study in the United States in which the denominator 
of patients with SCD was estimated from multiple and 
diverse linked data sources.12 Our mortality rates were 
similar to previous reports from the United States, 
Jamaica, and United Kingdom.4,7,8,10,20–24 Our method-
ology for describing mortality in SCD identified more 
deceased patients and a higher proportion of patients 
living longer than did the methodologies in previous 
reports.10,11 Our study identified 615 deaths among SCD 
patients in California and Georgia in 2004 through 
2008. Comparable NCHS CM data yielded 297 SCD 
deaths during the same five years (48% of the deceased 
SCD patients), whereas NCHS’s MCOD data yielded 
83% of the deceased patient count. More importantly 
for understanding SCD outcomes, we found the all-
cause mortality rate for the SCD population aged 5–74 
years to be noticeably higher than all-cause mortality 
rate for the African American population and the 
all-cause mortality rate for the general population of 
the same age. We also found a higher proportion of 
SCD patients dying in the older age groups than did 
previous research. 
Methodologically, our approach had several 
strengths over the previous research on SCD mortality. 
First, certain biases may be introduced when estimat-
ing survival from clinic-based populations, even when 
studied prospectively.2,3 Late entry, attrition, selection of 
a potentially more symptomatic population of patients, 
and better medical management are among a number 
of limitations of this approach. Because we were able to 
analyze SCD mortality using a population-based sample 
of patients with SCD, our surveillance effort included 
Figure 1. All-cause mortality rates for the sickle cell disease population identified through  
population-based surveillance (2004 through 2008), the African American population (2008),a  
and all populations (2008),a California and Georgia
aCenters for Disease Control and Prevention (US), National Center for Health Statistics. Multiple cause of death 1999–2013 [cited 2015 Dec 15]. 
Available from: http://wonder.cdc.gov/mcd.html 
372  Research
Public Health Reports / March–April 2016 / Volume 131
not only the fraction of the patient population being 
cared for by SCD experts, but also those who had care 
outside of sickle cell centers or were without medical 
homes or regular care providers. 
Another challenge for previous studies was estimat-
ing the underlying prevalence of SCD in the popula-
tion. Some researchers estimated it by using newborn 
screening data or by basing it on a portion of the 
total African American population.4,5 However, these 
methods may not account for those not identified by 
newborn screening or early mortality in patients with 
SCD. Newborn screening was not instituted until the 
1970s and did not become widespread in the United 
States until the late 1980s,3 raising the potential for the 
older population of patients to be underrepresented in 
previous studies. Estimates based on newborn screening 
data also do not include those who were born outside 
of the United States. 
Limitations
Although our study attempted to address many of 
the limitations of previous reports, several limitations 
remained. Only 23% of deceased SCD patients had a 
laboratory-confirmed diagnosis of SCD and were fol-
lowed in comprehensive SCD programs or identified 
via newborn screening; however, we believe the remain-
ing deceased individuals had a high probability of also 
being true SCD patients. These 472 patients without a 
laboratory-confirmed diagnosis were included as SCD 
patients based on multiple SCD-coded encounters in 
administrative datasets and relevant treatments, pro-
cedures, or complications that support the diagnosis; 
nevertheless, they did not have a known genotype, 
which limited the ability to determine mean and 
median ages at death by disease type. They may also 
differ significantly from the 143 SCD patients among 
whom the SCD genotype was confirmed because of the 
Figure 2. Number of deaths for sickle cell disease patients identified using NCHS’s compressed mortality reports 
(2004–2008),a NCHS’s multiple cause of death reports (2004–2008),b and population-based surveillance data 
(2004–2008), California and Georgia
aCenters for Disease Control and Prevention (US), National Center for Health Statistics. Multiple cause of death 1999–2013 [cited 2015 Dec 15]. 
Available from: http://wonder.cdc.gov/mcd.html
bCenters for Disease Control and Prevention (US), National Center for Health Statistics. Compressed mortality file 1999–2013 [cited 2015 Dec 
15]. Available from: http://wonder.cdc.gov/cmf-icd10.html
NCHS 5 National Center for Health Statistics
MCOD 5 multiple cause of death
SCD 5 sickle cell disease
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underlying differences in the ways these two groups 
were identified. The patients with confirmed genotypes 
were from newborn screening data or from specialty 
SCD programs, so they were likely younger than the 
general SCD population, and/or received comprehen-
sive care, and/or were referred to a specialty center 
because of the severity of their disease. 
Furthermore, although validation efforts used in 
the Registry and Surveillance System for Hemoglobin-
opathies study suggest a small error rate in using this 
approach of combining diagnosis and complications 
to identify patients,25 and our results were similar to 
other studies that examined the accuracy of using 
diagnosis codes for SCD patient finding,26 patients 
who were older and/or living with milder disease may 
be underrepresented in these data. Consequently, the 
normalization of the mortality rate among the oldest 
group of SCD patients may result from the underlying 
patient population’s small size (n567), a high propor-
tion of older patients who did not actually have SCD, 
yet met our study’s inclusion criteria, and/or an older 
population more likely to have milder disease and more 
likely to die from non-SCD-related causes. Further-
more, our methods did not allow us to  determine if 
Figure 3. Number of deaths for sickle cell disease patients identified using population-based surveillance data 
(2004–2008), state-based multiple cause of death (MCOD) data files (2004–2008), NCHS’s multiple cause of death 
reports (2004–2008),a and NCHS’s compressed mortality reports (2004–2008),b California and Georgia
aCenters for Disease Control and Prevention (US), National Center for Health Statistics. Multiple cause of death 1999–2013 [cited 2015 Dec 15]. 
Available from: http://wonder.cdc.gov/mcd.html
bCenters for Disease Control and Prevention (US), National Center for Health Statistics. Compressed mortality file 1999–2013 [cited 2015 Dec 
15]. Available from: http://wonder.cdc.gov/cmf-icd10.html
PBS 5 population-based surveillance 
MCOD 5 multiple cause of death 
NCHS 5 National Center for Health Statistics
SCD 5 sickle cell disease
Population-based 
surveillance data 
(n512,143)
State-based  
MCOD data 
(n51,513,507)
NCHS  
MCOD data 
(n51,513,507)
NCHS compressed 
mortality data 
(n51,513,507)
PBS patients in state-
based MCOD data 
(n5615)
State-based MCOD 
patients not linked to 
PBS (n5155)
With SCD underlying 
cause of death 
(n5216)
With SCD underlying 
cause of death  
(n581)
With SCD underlying 
cause of death 
(n5297)
With SCD underlying 
cause of death  
(n5297)
With SCD  
contributing cause  
of death (n5136)
With SCD  
contributing cause  
of death (n574)
With SCD  
contributing cause  
of death (n5216)
With no SCD  
cause of death 
(n5263)
SCD cause  
of death  
(n5513)
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identified patients moved out of California or Georgia 
during the five-year period and who, if so, should not 
have been included in the denominator for mortality 
calculations. Additionally, it is impossible to derive 
measures of central tendency from NCHS data (either 
the MCOD or CM files) because deaths are aggregated 
by age group; we therefore compared the means and 
medians reported in the earlier studies that are from 
earlier years of collected data and not specific to only 
these two states.4,5 Finally, this analysis includes only 
the 5% of the Registry and Surveillance System for 
Hemoglobinopathies patients who had died during a 
five-year period of observation from 2004 through 2008.
CONCLUSION
Surveillance data from the Registry and Surveillance 
System for Hemoglobinopathies project provides the 
most accurate data on mortality among the sickle cell 
population reported to date. Although SCD was once 
considered nearly universally fatal by adolescence, 
many patients are now living well into adulthood6 and 
surviving to 60 years of age or older.3 Documenting 
complications and outcomes during the life course 
informs development of standards of care, interven-
tions, and health-care policy to serve this population. 
It also highlights the importance of routine health 
screening for malignancies, diabetes, heart disease, 
and other non-SCD conditions common among older 
adults. Accurate assessment of life expectancy, causes 
of death, and disease prognosis requires long-term sur-
veillance using population-based registries of patients 
with SCD accurately diagnosed at birth.
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